RU2009121007A - Жирные спирты - Google Patents
Жирные спирты Download PDFInfo
- Publication number
- RU2009121007A RU2009121007A RU2009121007/04A RU2009121007A RU2009121007A RU 2009121007 A RU2009121007 A RU 2009121007A RU 2009121007/04 A RU2009121007/04 A RU 2009121007/04A RU 2009121007 A RU2009121007 A RU 2009121007A RU 2009121007 A RU2009121007 A RU 2009121007A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- omega
- lipid composition
- eicosapentaen
- docosahexaen
- Prior art date
Links
- 150000001298 alcohols Chemical class 0.000 title claims abstract 60
- 239000000203 mixture Substances 0.000 claims abstract 123
- 150000002632 lipids Chemical class 0.000 claims abstract 114
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract 26
- 239000000651 prodrug Substances 0.000 claims 59
- 229940002612 prodrug Drugs 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 21
- 235000015872 dietary supplement Nutrition 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- 229910010082 LiAlH Inorganic materials 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052744 lithium Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229960003194 meglumine Drugs 0.000 claims 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010014486 Elevated triglycerides Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- -1 lithium aluminum hydrides Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 235000019737 Animal fat Nutrition 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- KKQBNQXZNTVMBZ-UHFFFAOYSA-N docosa-1,3,5,7,9,11-hexaen-1-ol Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC=CO KKQBNQXZNTVMBZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940106134 krill oil Drugs 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/24—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85626806P | 2006-11-03 | 2006-11-03 | |
| US85626706P | 2006-11-03 | 2006-11-03 | |
| SE0602352-7 | 2006-11-03 | ||
| US60/856,267 | 2006-11-03 | ||
| US60/856,269 | 2006-11-03 | ||
| SE0602352 | 2006-11-03 | ||
| US60/856,268 | 2006-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009121007A true RU2009121007A (ru) | 2010-12-10 |
Family
ID=39876685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009121007/04A RU2009121007A (ru) | 2006-11-03 | 2007-11-02 | Жирные спирты |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100266681A1 (enExample) |
| JP (1) | JP2010509204A (enExample) |
| KR (1) | KR20090077081A (enExample) |
| CN (1) | CN101646426A (enExample) |
| BR (1) | BRPI0718393A2 (enExample) |
| CA (1) | CA2667153A1 (enExample) |
| MX (1) | MX2009004339A (enExample) |
| NO (1) | NO20092131L (enExample) |
| RU (1) | RU2009121007A (enExample) |
| WO (1) | WO2008139261A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009134147A1 (en) * | 2008-05-02 | 2009-11-05 | Pronova Biopharma Norge As | Lipid compositions containing derivatives of epa and dha an their use thereof |
| GB201009368D0 (en) * | 2010-06-04 | 2010-07-21 | Sana Pharma As | Dietary formulations |
| US8691297B2 (en) * | 2010-09-01 | 2014-04-08 | Nippon Suisan Kaisha, Ltd. | Alcoholic injury mitigating agent |
| CN104582507A (zh) * | 2012-06-11 | 2015-04-29 | 克利夫兰诊所基金会 | 心血管疾病和血栓形成的治疗与预防 |
| CN102860506A (zh) * | 2012-08-08 | 2013-01-09 | 辽宁省大连海洋渔业集团公司 | 磷虾油微囊粉及其制备方法 |
| PT2961727T (pt) * | 2013-02-28 | 2017-03-08 | Pronova Biopharma Norge As | Método de preparação do ácido 2-((5z,8z,11z,14z,17z)-icosa 5,8,11,14,17-pentaeniloxi)butanóico |
| EP2826384A1 (de) | 2013-07-16 | 2015-01-21 | Evonik Industries AG | Verfahren zur Trocknung von Biomasse |
| EP3200604B2 (de) | 2014-10-02 | 2025-05-07 | Evonik Operations GmbH | Verfahren zur herstellung eines futtermittels |
| BR112017006838B1 (pt) | 2014-10-02 | 2021-07-06 | Evonik Operations Gmbh | Processo para produzir um alimento para animais compreendendo biomassa contendo pufa, alimento para animais e método para criar animais |
| US11464244B2 (en) | 2014-10-02 | 2022-10-11 | Evonik Operations Gmbh | Feedstuff of high abrasion resistance and good stability in water, containing PUFAs |
| EP3200606B1 (de) | 2014-10-02 | 2021-03-31 | Evonik Operations GmbH | Verfahren zur herstellung eines pufas enthaltenden futtermittels durch extrusion einer pufas enthaltenden biomasse des typs labyrinthulomycetes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01207224A (ja) * | 1988-02-10 | 1989-08-21 | Nonogawa Shoji:Kk | 頭髪用化粧料及び養毛剤 |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| ATE384518T1 (de) * | 2000-01-31 | 2008-02-15 | Haerting S A | Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels |
| CN1665566A (zh) * | 2000-09-21 | 2005-09-07 | 营养21公司 | 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物 |
| EP1406641B1 (en) * | 2001-06-18 | 2009-01-07 | Neptune Technologies & Bioressources Inc. | Krill extracts for prevention and/or treatment of cardiovascular diseases |
| ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| BR0309740A (pt) * | 2002-05-03 | 2005-02-22 | Pronova Biocare As | Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos |
| WO2004018598A1 (ja) * | 2002-08-07 | 2004-03-04 | Kao Corporation | 油脂組成物 |
| US8017651B2 (en) * | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
| WO2004078166A2 (en) * | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Use of omega-3-fatty acids in the treatment of diabetic patients |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
-
2007
- 2007-11-02 CN CN200780040625A patent/CN101646426A/zh active Pending
- 2007-11-02 BR BRPI0718393-3A patent/BRPI0718393A2/pt not_active IP Right Cessation
- 2007-11-02 US US12/447,971 patent/US20100266681A1/en not_active Abandoned
- 2007-11-02 MX MX2009004339A patent/MX2009004339A/es not_active Application Discontinuation
- 2007-11-02 KR KR1020097011471A patent/KR20090077081A/ko not_active Ceased
- 2007-11-02 CA CA002667153A patent/CA2667153A1/en not_active Abandoned
- 2007-11-02 RU RU2009121007/04A patent/RU2009121007A/ru not_active Application Discontinuation
- 2007-11-02 WO PCT/IB2007/004590 patent/WO2008139261A2/en not_active Ceased
- 2007-11-02 JP JP2009535151A patent/JP2010509204A/ja active Pending
-
2009
- 2009-06-02 NO NO20092131A patent/NO20092131L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667153A1 (en) | 2008-11-20 |
| WO2008139261A2 (en) | 2008-11-20 |
| KR20090077081A (ko) | 2009-07-14 |
| CN101646426A (zh) | 2010-02-10 |
| US20100266681A1 (en) | 2010-10-21 |
| NO20092131L (no) | 2009-06-30 |
| BRPI0718393A2 (pt) | 2013-11-26 |
| MX2009004339A (es) | 2009-05-20 |
| WO2008139261A9 (en) | 2009-11-12 |
| WO2008139261A3 (en) | 2009-08-20 |
| JP2010509204A (ja) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509204A5 (enExample) | ||
| ES2256250T3 (es) | Combinaciones terapeuticas de acidos grasos. | |
| EP0084865B1 (en) | Propylene glycol diester solutions of pge-type compounds | |
| JP4596734B2 (ja) | スタチン副作用の処置 | |
| RU2376782C2 (ru) | Масляная композиция и содержащие ее пищевые продукты, фармацевтическая композиция и пищевая добавка | |
| EP0003407B1 (en) | Pharmaceutical and dietary composition comprising gamma-linolenic acids | |
| US5650157A (en) | Pharmaceutical compositions and methods | |
| JP2019001823A (ja) | ω３脂肪酸の自己乳化組成物 | |
| JPH07502491A (ja) | 皮膚疾患の治療に対して静脈的に投与される薬剤を調整するためのエマルジョンの使用 | |
| US20060078625A1 (en) | Compositions including krill extracts and conjugated linoleic acid and methods of using same | |
| JPH11209279A (ja) | 体重減少および肥満処置の方法 | |
| JP5087280B2 (ja) | 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 | |
| RU2011141102A (ru) | Обогащенные омега-3 рыбные парентеральные питательные эмульсии типа масло в воде | |
| JPH08169823A (ja) | 糖尿病合併症治療用組成物 | |
| US6177470B1 (en) | Methods of treatment using ascorbyl gamma linolenic acid or ascorbyl dihomo-gamma-linolenic acid | |
| BRPI0718393A2 (pt) | Álcoois de ácido graxo | |
| JP2775627B2 (ja) | 治療用組成物 | |
| WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| CN103347508A (zh) | 使用脂质化合物的治疗方法 | |
| JP2010508261A (ja) | 新規脂質化合物 | |
| US6348609B1 (en) | Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (HODE) or the esters thereof from a mixture containing linoleic acid or the esters thereof | |
| JPH0761954B2 (ja) | コレステロール低下または上昇抑制剤 | |
| CN102416056A (zh) | 一种降血脂复方纳米乳口服液及其制备方法 | |
| JP2025508912A5 (enExample) | ||
| US20070270376A1 (en) | Combinations of Hyaluronic Acid and Polyunsaturated Fatty Acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20140808 |